Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Asset Turnover Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Monte Rosa Therapeutics Inc Asset Turnover Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The asset turnover ratio measures a company's efficiency in utilizing its assets to generate revenue. It is calculated by dividing the company's revenue by the average of its total assets and total non-current assets. This ratio indicates how effectively a company generates sales from its asset base. A higher ratio implies better asset utilization and revenue generation, while a lower ratio may suggest underutilization of assets or inefficient operations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Monte Rosa Therapeutics Inc Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Monte Rosa Therapeutics Inc Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Monte Rosa Therapeutics Inc Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email